FROM MICE TO MAN - THE PRECLINICAL HISTORY OF MYCOPHENOLATE MOFETIL

In vitro studies demonstrating that mycophenolic acid (MPA) held promi se as a powerful immunosuppressant led to a series of in vivo studies to further evaluate this interesting new agent. Experiments in mice sh owed that MPA had powerful lymphocyte selective immunosuppressive effe cts. A prodrug of MPA, mycophenolate mofetil (MMF), was developed to i mprove bioavailability on oral administration. Numerous tests demonstr ated that MMF, alone or in combination with other immunosuppressives, prolonged allograft survival of various organs in several species and may be useful for reversing ongoing rejection. MMF also was found to b e useful in prolonging xenograft survival. These animal experiments in dicated that MMF had the benefit of relatively low toxicity and a good safety profile and drove early clinical trials of MMF. These trials s howed that MMF is relatively safe and well tolerated in man and is of potential use for the prevention and treatment of acute allograft reje ction. This article describes the preclinical history of the developme nt of MMF, concentrating on the animal experiments and phase I and II trials that preceded the large-scale clinical testing of this new immu dosuppressant.